Maxx’s Top Stock for September
Advisor: Maxx Chatsko
There are many emerging opportunities in the biopharmaceutical sector, but few are ready to be commercialized and generate profits right now. 7investing Lead Advisor Maxx Chatsko’s Top Stock for September is already cashing in and has plenty of room for growth. In fact, the company plans to have up to six drugs on the market by the end of 2025, up from only one today.
My top stock to buy this month is an undervalued leader in an emerging field of the biopharmaceutical sector.
I’m 7investing Lead Advisor Maxx Chatsko. Our team here at 7investing empowers you to build long-term wealth by publishing our seven best stock market opportunities each month, each backed by the domain competence of one of our advisors.
My pick for September, and my first ever pick here at 7investing, is a biopharmaceutical company that’s best-suited for investors who have a long-term mindset, who have an appetite for risk, and who are pursuing growth stocks.
Now, this company comes with all of the risks of a drug developer, including clinical trials, manufacturing, regulatory headaches. But it does have a commercialized product on the market today and it’s profitable.
In fact, this stock trades well below industry peers relative to sales and earnings.
Now, it’s not a household name by any means, but it is well-positioned to lead this emerging opportunity within the biopharmaceutical sector.
For example, the company is targeting launching up to five new drugs on the market by the end of 2025. And, with drug prices being such a hot-button issue lately, investors should know that this company is actually expanding patient access to innovative biologic drugs due to how it prices its products. So it’s a great example of how a business can do well by also doing good.
If you want to read my full write up with all of the risks, challenges, and opportunities for this company, then please visit 7investing.com. We are here to empower you to invest in your future. We’re 7investing.